Abstract
Melatonin (N-acetyl-5-methoxytryptamine) is synthesized and released by the pineal gland following a circadian rhythm characterized by high levels during the night. It shows several pharmacological effects on diverse cellular and animal models, mainly related to either its antioxidant activity or to its ability to activate specific receptors (MTr). Melatonin is widely used as a self-administered food additive, but its therapeutic potential needs more investigation and is hampered by its poor pharmacokinetics. This review will focus on the medicinal chemistry of agonist ligands of the two human GPCRs MT1 and MT2 melatonin receptors. The recent introduction of ramelteon, a non-selective MT1/MT2 agonist for the treatment of insomnia, and the advancement to clinical trials of other MTr agonists have renewed interest for different classes of compounds endowed with this activity. Several chemical classes of MTr agonists are described in the literature, generally characterized by an indole, or an indole bioisostere, carrying an amide side chain and a methoxy group, or substituents with similar stereoelectronic features. Abundant information is available for nonselective MT1/MT2 ligands, and several molecular models, both ligand- and receptor-based, have been proposed to rationalize their structure activity relationships. Fewer classes of selective agonists have been reported in the literature, and they could help clarifying the physiological role of the two receptor subtypes. A brief discussion on the therapeutic potential of this class of compounds is based on the clinical data available for the agonists ramelteon, agomelatine, β- methyl-6-chloromelatonin (TIK-301) and VEC-162.
Current Topics in Medicinal Chemistry
Title: Melatonin Receptor Agonists: SAR and Applications to the Treatment of Sleep-Wake Disorders
Volume: 8 Issue: 11
Author(s): Silvia Rivara, Marco Mor, Annalida Bedini, Gilberto Spadoni and Giorgio Tarzia
Affiliation:
Abstract: Melatonin (N-acetyl-5-methoxytryptamine) is synthesized and released by the pineal gland following a circadian rhythm characterized by high levels during the night. It shows several pharmacological effects on diverse cellular and animal models, mainly related to either its antioxidant activity or to its ability to activate specific receptors (MTr). Melatonin is widely used as a self-administered food additive, but its therapeutic potential needs more investigation and is hampered by its poor pharmacokinetics. This review will focus on the medicinal chemistry of agonist ligands of the two human GPCRs MT1 and MT2 melatonin receptors. The recent introduction of ramelteon, a non-selective MT1/MT2 agonist for the treatment of insomnia, and the advancement to clinical trials of other MTr agonists have renewed interest for different classes of compounds endowed with this activity. Several chemical classes of MTr agonists are described in the literature, generally characterized by an indole, or an indole bioisostere, carrying an amide side chain and a methoxy group, or substituents with similar stereoelectronic features. Abundant information is available for nonselective MT1/MT2 ligands, and several molecular models, both ligand- and receptor-based, have been proposed to rationalize their structure activity relationships. Fewer classes of selective agonists have been reported in the literature, and they could help clarifying the physiological role of the two receptor subtypes. A brief discussion on the therapeutic potential of this class of compounds is based on the clinical data available for the agonists ramelteon, agomelatine, β- methyl-6-chloromelatonin (TIK-301) and VEC-162.
Export Options
About this article
Cite this article as:
Rivara Silvia, Mor Marco, Bedini Annalida, Spadoni Gilberto and Tarzia Giorgio, Melatonin Receptor Agonists: SAR and Applications to the Treatment of Sleep-Wake Disorders, Current Topics in Medicinal Chemistry 2008; 8 (11) . https://dx.doi.org/10.2174/156802608784936719
DOI https://dx.doi.org/10.2174/156802608784936719 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
α<sub>2</sub> Adrenoceptor: a Target for Neuropathic Pain Treatment
Mini-Reviews in Medicinal Chemistry Subject Index To Volume 6
Endocrine, Metabolic & Immune Disorders - Drug Targets Evaluation of Allergic Reactions Following Intravenous Infusion of Polyvalent Antivenom in Snakebite Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry An Exceptional Case of Atrial Fibrillation Arrhythmia Induced by Etoposide
Current Drug Safety Editorial [Hot Topic: Cardiovascular Risk and Inflammation: Pathophysiological Mechanisms, Drug Design, and Targets Executive (Guest Editor: Armen Yuri Gasparyan)]
Current Pharmaceutical Design Mechanisms Underlying the Hepatotoxic Effects of Ecstasy
Current Pharmaceutical Biotechnology Schizophrenia: Causes and Treatments
Current Pharmaceutical Design A Case of Ischemic Stroke in Acute Promyelocytic Leukemia at Initial Presentation: Relevance of All-Trans Retinoic Acid Treatment
Cardiovascular & Hematological Disorders-Drug Targets Vasorelaxation Caused by Cannabinoids: Mechanisms in Different Vascular Beds
Current Vascular Pharmacology Neurotrophic Factors as a Protective Strategy in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets ALDH2---The Genetic Polymorphism and Enzymatic Activity Regulation: Their Epidemiologic and Clinical Implications
Current Drug Targets Mechanisms And Prevention Of TAVI-Related Cerebrovascular Events
Current Pharmaceutical Design TRPV1 Function in Health and Disease
Current Pharmaceutical Biotechnology Freezing of Gait in Parkinsonism and its Potential Drug Treatment
Current Neuropharmacology β-Carboline Alkaloids: Biochemical and Pharmacological Functions
Current Medicinal Chemistry Clinical Analysis Methods of Voice Disorders
Current Bioinformatics Initiating Structural Studies Of Lys49-Pla2 Homologues Complexed With An Anionic Detergent, A Fatty Acid And A Natural Lipid
Protein & Peptide Letters Rho-kinase (ROCK) Inhibitors - A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility
Current Medicinal Chemistry Alpha-2 Adrenoceptor Ligands and Opioid Drugs: Pharmacological Interactions of Therapeutic Interest
Current Neuropharmacology Recent Development in Identification of Potential Novel Therapeutic Targets Against Trypanosomatids
Current Topics in Medicinal Chemistry